Skip to main content
. 2018 Dec 20;52(6):1801100. doi: 10.1183/13993003.01100-2018

FIGURE 1.

FIGURE 1

Distribution of the efficacy–effectiveness (EE) factor based on start date of first-line systemic treatment, per regimen. For all regimens the median EE factor is significantly different from test value 1.0 (one-sample Wilcoxon signed-rank test), with p-values of p<0.05. cis: cisplatin; pem: pemetrexed; gemci: gemcitabine; carbo: carboplatin; beva: bevacizumab; pacli: paclitaxel; doce: docetaxel.